HIMS · Hims & Hers Health, Inc.

Current Thesis

The reaccel trough is in and a second narrative leg has shown up. Q1 2026 (reported ~2026-05-11) was the kitchen-sink print revenue $608M, only +4% YoY, missing the $616-619M estimate, with adj. EBITDA squeezed to $44M (7% margin) by ~$33M of restructuring tied to exiting compounded semaglutide. But the forward guide inflects hard: Q2 2026 guided $680-700M (+25-28% YoY), FY raised to $2.8-3.0B (+19-28%), adj. EBITDA $275-350M, on the branded Wegovy ramp (125,000+ shipments in the first 6 weeks). What changed in the last week: sell-side flipped from cold to warming Canaccord reiterated Buy with a $32 target on 2026-06-03 framing peptides/longevity as a multi-year driver, Needham sits at $35, and both now print ABOVE spot. A new CMO (Anant Vinjamoori, longevity/preventive) was named 2026-06-04 and the stock popped 7.23% to $29.50 on it. The setup: real reacceleration plus a fresh peptides story, but price is extended after a single-name froth pop into a two-month catalyst gap, and this remains a violently squeeze-coded name. The clean entry is a pullback toward the $24-26 shelf, not the $29 chase.

Bull Case

• Guide reaccel off a trough print: Q2 2026 guided $680-700M = +25-28% YoY, a sharp inflection off Q1's +4% ($608M); FY raised to $2.8-3.0B (issued with the ~2026-05-11 Q1 print).
• Branded Wegovy ramp converting: 125,000+ Wegovy shipments in the first 6 weeks post-launch, tracking 100k+ new weight-loss subscribers per month (Q1 call, May 2026).
• Sell-side warming, now above spot: Canaccord Buy / $32 (2026-06-03, peptides multi-year thesis) and Needham $35 (raised 2026-05-12) sit above the ~$29 tape the upgrade fuel that was absent last week now exists. Consensus is Buy across ~13 analysts.
• New narrative leg peptides/longevity: CMO Anant Vinjamoori appointed 2026-06-04 (preventive/longevity background); stock +7.23% to $29.50 same day. Extends the story beyond pure GLP-1 distribution.
• Insider conviction floor: CFO David Wells bought 48,400 sh @ $24.23 (~$1.17M) open-market on 2026-05-27 (Form 4); now ~20% in the money.
• Global platform build-out funded: ~$1.15B Eucalyptus acquisition (Australia/UK/Germany/Japan/Canada) completed, backed by an upsized $350M convertible priced May 2026 international expansion + AI investment without burning cash reserves.
• Tape repaired short-term: reclaimed the 20-, 50- (~$24.31) and 100-day MAs and the insider basis; +100%+ off the 2026-02-27 $13.74 low.

Bear Case

• Q1 2026 was a miss: $608M rev (+4% YoY) vs. $616-619M est; 7% EBITDA margin gutted by ~$33M restructuring growth decelerated to a crawl immediately before the reaccel promise.
• Guide is a promise, first proof not until ~2026-08-10: the +25-28% Q2 reaccel needs the Wegovy ramp to hold; until the August print it is a story stock trading above its average target on momentum.
• The +7% pop was idiosyncratic, not cluster: a CMO hire driving a 7% single-day move is froth, not a fundamental catalyst exactly the kind of move this name round-trips. No DTC telehealth peer is breaking out alongside it.
• Convertible dilution overhead: the $350M notes convert near $29.53 (32.5% premium over a $22.29 reference); that level is mechanical overhead supply sitting right at spot.
• Competition closing in: CVS reintroduced Zepbound as a covered medication (2026-05-28); Novo and Lilly run their own DTC channels; broadening PBM/employer coverage of branded GLP-1 erodes the cash-pay value prop HIMS monetizes.
• Single-category concentration / partner risk: weight-loss is the engine, and Novo already terminated once in 2025. A re-termination, GLP-1 regulatory shift, or pricing war hits the whole thesis at once.
• Long-term downtrend intact: still below the 200-day MA; down ~45% over 12 months off the $70.43 52-week high. The multi-month trend has not flipped.
• Squeeze-prone: repeated whale / unusual-options flags (2026-05-25, 2026-06-03, 2026-06-05); the name can shed 20-30% in a week.

Setup & Price Structure

Last ~$28.78 (2026-06-04 close), with an intraday spike to $29.50 (+7.23%) on the CMO news. 52-week range $13.74-$70.43. Price has reclaimed the 20/50/100-day MAs but remains below the 200-day short-term repaired, long-term downtrend not yet broken. Overhead, the $29.53 convertible conversion level acts as supply, and the average analyst target (~$26.61-$32.46 depending on source) brackets spot Canaccord $32 and Needham $35 are the bull markers, BofA $25 and Truist $23 the laggards. Entry math: chasing $29 into a two-month catalyst gap on a squeeze-coded name is poor reward/risk; the asymmetric add is a controlled pullback to the $24-26 shelf where the insider basis and 50-day backstop the trade.

Catalyst Calendar (next 30 days)

• No scheduled binary catalyst inside the 2026-06-07 → 2026-07-07 window. The next hard event is the Q2 2026 print (~2026-08-10), which is outside 30 days hence catalyst_date null.
• Ongoing analyst re-rating (continuous): Canaccord $32 reiterated 2026-06-03; watch for additional Street targets migrating above spot, which would confirm the warming.
• Continued options/whale flow flags: logged 2026-05-25, 2026-06-03, 2026-06-05 momentum/squeeze confirmation, watch for it drying up as an early top tell.
• Eucalyptus integration / international rollout updates (est. ongoing through 2026): any execution color on the Australia/UK/Germany/Japan/Canada platform.
• Convertible settlement mechanics (May-2026 issue): hedging flows around the ~$29.53 conversion level can cap or accelerate moves near spot.

What Would Change Our Mind

• Bull confirmation: a daily close and hold above $30 — that clears the $29.53 convertible overhead on expanding volume, plus a second above-spot Street upgrade, would convert the recovery base into a trend leg and justify pressing rather than waiting for a pullback.
• Thesis break (cut): a daily close below $24 forfeits the 50-day MA (~$24.31) and the $24.23 insider basis recovery structure broken, no merit to holding.
• Hard invalidators: any Novo Nordisk partnership-termination headline (a 2025 repeat); Q2 revenue printing below the $680M low-end guide on ~2026-08-10; or GLP-1 reimbursement expansion (CVS/PBM) visibly cannibalizing cash-pay subscriber adds in the Q2 metrics.
• Saturation tell: mainstream/CNBC weight-loss-hype coverage spiking while whale-options flow dries up late-stage retail distribution, trim into it.

Correlation Notes

• GLP-1 supply chain: directly geared to Novo Nordisk (NVO) the branded Wegovy ramp is the revenue bridge, and a Novo headline moves HIMS more than its own fundamentals. Eli Lilly (LLY) and its Zepbound/CVS coverage are the competitive read-through.
• DTC telehealth / consumer-health subscription: moves with the digital-health risk-on/off tape (TDOC, GoodRx-type names) but increasingly idiosyncratic given the GLP-1 distribution model.
• High-beta retail-momentum basket: as an a6 squeeze name, HIMS correlates more tightly to small/mid-cap risk appetite and options-flow regimes than to healthcare sector beta it trades like a momentum vehicle, not a defensive healthcare name.
• Rate/risk sensitivity: the $350M convertible and growth-multiple profile make it sensitive to risk-off and rising-rate regimes that compress unprofitable-growth multiples.